ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9606G>C (p.Pro3202=) (rs755890067)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000495413 SCV000578903 likely benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/).
Ambry Genetics RCV000163813 SCV000214397 likely benign Hereditary cancer-predisposing syndrome 2014-09-15 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Invitae RCV000199254 SCV000253062 benign Hereditary breast and ovarian cancer syndrome 2020-12-06 criteria provided, single submitter clinical testing
GeneDx RCV000433154 SCV000512400 likely benign not specified 2017-10-27 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000433154 SCV000600871 likely benign not specified 2017-05-23 criteria provided, single submitter clinical testing
Color Health, Inc RCV000163813 SCV000684077 benign Hereditary cancer-predisposing syndrome 2016-05-16 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000433154 SCV000918912 likely benign not specified 2019-06-03 criteria provided, single submitter clinical testing Variant summary: BRCA2 c.9606G>C alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4.4e-05 in 251382 control chromosomes (gnomAD). This frequency is not higher than the expected maximum for a pathogenic variant in BRCA2 causing Hereditary Breast and Ovarian Cancer (4.4e-05 vs 0.00075), allowing no conclusion about variant significance. c.9606G>C has been reported in the literature in affected individuals without strong evidence for causality (Borg_2010, Caux-Moncoutier_2011, Minucci_2015). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. A co-occurrence with a pathogenic variant has been reported (BRCA1 c.4183C>T (p.Gln1395X); UMD database), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six submitters, including one expert panel (ENIGMA) have provided clinical-significance assessments for this variant in ClinVar after 2014 without evidence for independent evaluation, and classified the variant as likely benign (4x) / benign (2x). Based on the evidence outlined above, the variant was classified as likely benign.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001287475 SCV001474168 likely benign none provided 2020-03-18 criteria provided, single submitter clinical testing
True Health Diagnostics RCV000163813 SCV000787961 likely benign Hereditary cancer-predisposing syndrome 2018-01-15 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001355767 SCV001550739 likely benign Malignant tumor of breast no assertion criteria provided clinical testing The BRCA2 p.Pro3202= variant was identified in a cohort of ovarian cancer patients and classified as having no clinical significance (Minucci 2015). The variant was also identified in dbSNP (ID: rs755890067) as With Likely benign allele, ClinVar (classified as benign by Color Genomic and Invitae; classified as likely benign by Ambry Genetics, GeneDx, ENIGMA, and one other clinical laboratory), Clinvitae, LOVD 3.0 (4x), and UMD-LSDB (15x as uncertain significance; co-occurring with the pathogenic BRCA1 variant c.4183C>T, p.Gln1395X). The variant was not identified in GeneInsight-COGR, Cosmic, BIC Database, ARUP Laboratories, or the Zhejiang University Database. The variant was identified in control databases in 11 of 246166 chromosomes at a frequency of 0.0001 (Genome Aggregation Database Feb 27, 2017). Breakdown of the observations by population include European in 11 of 111642 chromosomes (freq: 0.0001), while the variant was not observed in the African, Other, Latino, Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. The p.Pro3202= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, the clinical significance of this variant cannot be determined with certainty at this time, although available information suggests a benign role. This variant is classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.